Cargando…

Formulation and Evaluation of Levofloxacin and Betamethasone Ophthalmic Emulgel

OBJECTIVE: Drug delivery to ocular tissues is challenging due to rapid removal of instilled drug due to low resident time in ocular tissues. The aim of the study was to formulate an ophthalmic emulgel that delivers two drugs (betamethasone sodium phosphate [BSP] and levofloxacin). The new combinatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabry, Hiba Sabah, Al-Shohani, Athmar Dhahir Habeeb, Mahmood, Sura Zuhair
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291107/
https://www.ncbi.nlm.nih.gov/pubmed/34349481
http://dx.doi.org/10.4103/jpbs.JPBS_338_20
_version_ 1783724583716651008
author Sabry, Hiba Sabah
Al-Shohani, Athmar Dhahir Habeeb
Mahmood, Sura Zuhair
author_facet Sabry, Hiba Sabah
Al-Shohani, Athmar Dhahir Habeeb
Mahmood, Sura Zuhair
author_sort Sabry, Hiba Sabah
collection PubMed
description OBJECTIVE: Drug delivery to ocular tissues is challenging due to rapid removal of instilled drug due to low resident time in ocular tissues. The aim of the study was to formulate an ophthalmic emulgel that delivers two drugs (betamethasone sodium phosphate [BSP] and levofloxacin). The new combination will allow the simultaneous administration and extended release of the two drugs which potentially improve resident time in ocular tissues, patient compliance, and adherence to treatment. MATERIALS AND METHODS: Formulations containing different gelling agents at different concentrations were prepared to choose the optimum combination regarding physical properties and release. The emulgel formulations F1, F2, F3, and F4 were made using gelling agent 1% and 2% xanthan gum, 1% carbopole 934, and 2% methyl cellulose, respectively. F5 was formulated using 2% methyl cellulose with double the amount of poloxamer 188 as emulsifying agent. All the formulations were examined regarding their physical appearance, pH, viscosity, drug content, and in vitro drug release. The optimum formula was also examined for antibacterial activity. RESULTS: The results demonstrated that F5 was the optimum formulation having a proper physical characteristics and release profile of both drugs, 96% and 90% for BSP and levofloxacin, respectively, compared to other formulations and commercial eye drops. CONCLUSION: Simultaneous and extended release of the two drugs was achieved using one formulation of emulgel. The ability to deliver hydrophilic and hydrophobic drug through the same formulation without the need to use two drops will improve patient compliance and hence patient adherence to treatment.
format Online
Article
Text
id pubmed-8291107
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-82911072021-08-03 Formulation and Evaluation of Levofloxacin and Betamethasone Ophthalmic Emulgel Sabry, Hiba Sabah Al-Shohani, Athmar Dhahir Habeeb Mahmood, Sura Zuhair J Pharm Bioallied Sci Original Article OBJECTIVE: Drug delivery to ocular tissues is challenging due to rapid removal of instilled drug due to low resident time in ocular tissues. The aim of the study was to formulate an ophthalmic emulgel that delivers two drugs (betamethasone sodium phosphate [BSP] and levofloxacin). The new combination will allow the simultaneous administration and extended release of the two drugs which potentially improve resident time in ocular tissues, patient compliance, and adherence to treatment. MATERIALS AND METHODS: Formulations containing different gelling agents at different concentrations were prepared to choose the optimum combination regarding physical properties and release. The emulgel formulations F1, F2, F3, and F4 were made using gelling agent 1% and 2% xanthan gum, 1% carbopole 934, and 2% methyl cellulose, respectively. F5 was formulated using 2% methyl cellulose with double the amount of poloxamer 188 as emulsifying agent. All the formulations were examined regarding their physical appearance, pH, viscosity, drug content, and in vitro drug release. The optimum formula was also examined for antibacterial activity. RESULTS: The results demonstrated that F5 was the optimum formulation having a proper physical characteristics and release profile of both drugs, 96% and 90% for BSP and levofloxacin, respectively, compared to other formulations and commercial eye drops. CONCLUSION: Simultaneous and extended release of the two drugs was achieved using one formulation of emulgel. The ability to deliver hydrophilic and hydrophobic drug through the same formulation without the need to use two drops will improve patient compliance and hence patient adherence to treatment. Wolters Kluwer - Medknow 2021 2021-05-26 /pmc/articles/PMC8291107/ /pubmed/34349481 http://dx.doi.org/10.4103/jpbs.JPBS_338_20 Text en Copyright: © 2021 Journal of Pharmacy and Bioallied Sciences https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Sabry, Hiba Sabah
Al-Shohani, Athmar Dhahir Habeeb
Mahmood, Sura Zuhair
Formulation and Evaluation of Levofloxacin and Betamethasone Ophthalmic Emulgel
title Formulation and Evaluation of Levofloxacin and Betamethasone Ophthalmic Emulgel
title_full Formulation and Evaluation of Levofloxacin and Betamethasone Ophthalmic Emulgel
title_fullStr Formulation and Evaluation of Levofloxacin and Betamethasone Ophthalmic Emulgel
title_full_unstemmed Formulation and Evaluation of Levofloxacin and Betamethasone Ophthalmic Emulgel
title_short Formulation and Evaluation of Levofloxacin and Betamethasone Ophthalmic Emulgel
title_sort formulation and evaluation of levofloxacin and betamethasone ophthalmic emulgel
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291107/
https://www.ncbi.nlm.nih.gov/pubmed/34349481
http://dx.doi.org/10.4103/jpbs.JPBS_338_20
work_keys_str_mv AT sabryhibasabah formulationandevaluationoflevofloxacinandbetamethasoneophthalmicemulgel
AT alshohaniathmardhahirhabeeb formulationandevaluationoflevofloxacinandbetamethasoneophthalmicemulgel
AT mahmoodsurazuhair formulationandevaluationoflevofloxacinandbetamethasoneophthalmicemulgel